Overview

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Status:
RECRUITING

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.

Phase:

PHASE2

Details

Lead Sponsor:

University of Michigan Rogel Cancer Center

Collaborators:

National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)

Treatments:

Deferasirox
Iron Chelating Agents